Kokufu Ikuo, Taniguchi Hirokazu, Kimura Fumihiko, Fukuda Kazuhiro, Yamamoto Masayuki, Yano Tokiharu, Yamada Katsumi
Dept. of Surgery, Itami City Hospital.
Gan To Kagaku Ryoho. 2002 Feb;29(2):221-6.
We treated 12 patients with metastatic breast cancer with weekly paclitaxel therapy. Paclitaxel was administrated by 1 hour infusion at a dose of 80 mg/m2 after short premedication every week on an outpatient basis. Administration was continued for 3 weeks followed by 1 week rest. All patients had received prior metastatic chemotherapy, and prior anthracycline therapy was done in 66.7% of the patients. Partial responses were observed in 66.7% of the patients and progressive disease in 33.3%. The response rate was 66.7%. Responses were observed in 62.5% of the patients with prior anthracycline therapy. Grade 3/4 leukopenia and neutropenia occurred in 25% of the patients, respectively, and no grade 3/4 peripheral neuropathy was observed. Dyspnea occurred in 25% of the patients and was grade 3 in 16.7%. Dyspnea is thought to be one of the adverse events requiring caution with weekly paclitaxel administration. Weekly paclitaxel therapy is effective and well tolerated in patients with metastatic breast cancer.
我们对12例转移性乳腺癌患者采用每周一次的紫杉醇治疗。门诊患者每周在简短预处理后，以80mg/m²的剂量静脉输注紫杉醇1小时。持续给药3周，随后休息1周。所有患者均接受过先前的转移性化疗，66.7%的患者接受过蒽环类药物治疗。66.7%的患者观察到部分缓解，33.3%的患者疾病进展。缓解率为66.7%。接受过蒽环类药物治疗的患者中，62.5%观察到缓解。25%的患者分别出现3/4级白细胞减少和中性粒细胞减少，未观察到3/4级周围神经病变。25%的患者出现呼吸困难，其中16.7%为3级。呼吸困难被认为是每周使用紫杉醇时需要谨慎对待的不良事件之一。每周一次的紫杉醇治疗对转移性乳腺癌患者有效且耐受性良好。
